 | • レポートコード：MRC2304A121 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、229ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に2,579.36百万ドルであった世界の発作性夜間ヘモグロビン尿症（PNH）治療市場規模が2022年に2,852.86百万ドルに到達し、2027年までにCAGR 10.78％で成長して4,767.48百万ドルへと拡大すると予測しています。当調査資料では、発作性夜間ヘモグロビン尿症（PNH）治療の世界市場について多角的な視点から分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、診断検査別（骨髄検査、完全血球数検査（CBC）、フローサイトメトリー、乳酸脱水素酵素試験（LDH）、ヘモジデリン尿検査）分析、治療別（輸血、投薬、幹細胞移植）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめました。なお、当書内の企業情報としては、Accela ChemBio Inc、Achillion Pharmaceuticals、Akari Therapeutics、Alexion Pharmaceuticals, lnc.、Alnylam Pharmaceuticals, Inc.、Amgen Inc、Amyndas Pharmaceuticals、Apellis Pharmaceuticals、Asymchem Inc.、Avara Pharmaceutical Services, Inc.などが掲載されています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の発作性夜間ヘモグロビン尿症（PNH）治療市場規模：診断検査別 - 骨髄検査の市場規模 - 完全血球数検査（CBC）の市場規模 - フローサイトメトリーの市場規模 - 乳酸脱水素酵素試験（LDH）の市場規模 - ヘモジデリン尿検査の市場規模 ・世界の発作性夜間ヘモグロビン尿症（PNH）治療市場規模：治療別 - 輸血における市場規模 - 投薬における市場規模 - 幹細胞移植における市場規模 ・世界の発作性夜間ヘモグロビン尿症（PNH）治療市場規模：地域別 - 南北アメリカの発作性夜間ヘモグロビン尿症（PNH）治療市場規模 アメリカの発作性夜間ヘモグロビン尿症（PNH）治療市場規模 カナダの発作性夜間ヘモグロビン尿症（PNH）治療市場規模 ブラジルの発作性夜間ヘモグロビン尿症（PNH）治療市場規模 ... - アジア太平洋の発作性夜間ヘモグロビン尿症（PNH）治療市場規模 日本の発作性夜間ヘモグロビン尿症（PNH）治療市場規模 中国の発作性夜間ヘモグロビン尿症（PNH）治療市場規模 インドの発作性夜間ヘモグロビン尿症（PNH）治療市場規模 韓国の発作性夜間ヘモグロビン尿症（PNH）治療市場規模 台湾の発作性夜間ヘモグロビン尿症（PNH）治療市場規模 ... - ヨーロッパ/中東/アフリカの発作性夜間ヘモグロビン尿症（PNH）治療市場規模 イギリスの発作性夜間ヘモグロビン尿症（PNH）治療市場規模 ドイツの発作性夜間ヘモグロビン尿症（PNH）治療市場規模 フランスの発作性夜間ヘモグロビン尿症（PNH）治療市場規模 ロシアの発作性夜間ヘモグロビン尿症（PNH）治療市場規模 ... - その他地域の発作性夜間ヘモグロビン尿症（PNH）治療市場規模 ・競争状況 ・企業情報 |
The Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market size was estimated at USD 2,579.36 million in 2021 and expected to reach USD 2,852.86 million in 2022, and is projected to grow at a CAGR 10.78% to reach USD 4,767.48 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Paroxysmal Nocturnal Hemoglobinuria Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Diagnostic Test, the market was studied across Bone Marrow Examination, Complete Blood Count Test (CBC), Flow Cytometry, Lactate Dehydrogenase Test (LDH), and Urine Test for Hemosiderin.
Based on Treatment, the market was studied across Blood Transfusion, Medication, and Stem Cell Transplant.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Paroxysmal Nocturnal Hemoglobinuria Treatment market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market, including Accela ChemBio Inc, Achillion Pharmaceuticals, Akari Therapeutics, Alexion Pharmaceuticals, lnc., Alnylam Pharmaceuticals, Inc., Amgen Inc, Amyndas Pharmaceuticals, Apellis Pharmaceuticals, Asymchem Inc., Avara Pharmaceutical Services, Inc., BIOCAD, CinnaGen Co, Ectica Technologies AG, F. Hoffmann-La Roche AG, GE Healthcare, IRISYS, LLC, Johnson & Johnson, Mayne Pharma International Pty Ltd, Novartis AG, Ra Pharmaceuticals, Regeneron Pharmaceuticals, Inc, Samsung Bioepis, Thermo Fisher Scientific Inc., and Unither Pharmaceuticals.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market?
6. What is the market share of the leading vendors in the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing adoption of novel therapeutics
5.1.1.2. Rising geriatric population and the emergence of biologics
5.1.1.3. Growing number of blood and bone marrow related disorders
5.1.2. Restraints
5.1.2.1. High costs associated with medical treatment
5.1.3. Opportunities
5.1.3.1. Increasing development in stem cell research
5.1.3.2. Rising investment in research & development of PNH treatment drugs
5.1.4. Challenges
5.1.4.1. Adverse side effects with existing treatments
5.2. Cumulative Impact of COVID-19
6. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Diagnostic Test
6.1. Introduction
6.2. Bone Marrow Examination
6.3. Complete Blood Count Test (CBC)
6.4. Flow Cytometry
6.5. Lactate Dehydrogenase Test (LDH)
6.6. Urine Test for Hemosiderin
7. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Treatment
7.1. Introduction
7.2. Blood Transfusion
7.3. Medication
7.4. Stem Cell Transplant
8. Americas Paroxysmal Nocturnal Hemoglobinuria Treatment Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Accela ChemBio Inc
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. Achillion Pharmaceuticals
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. Akari Therapeutics
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. Alexion Pharmaceuticals, lnc.
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. Alnylam Pharmaceuticals, Inc.
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. Amgen Inc
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. Amyndas Pharmaceuticals
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. Apellis Pharmaceuticals
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. Asymchem Inc.
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. Avara Pharmaceutical Services, Inc.
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services
12.11. BIOCAD
12.11.1. Business Overview
12.11.2. Key Executives
12.11.3. Product & Services
12.12. CinnaGen Co
12.12.1. Business Overview
12.12.2. Key Executives
12.12.3. Product & Services
12.13. Ectica Technologies AG
12.13.1. Business Overview
12.13.2. Key Executives
12.13.3. Product & Services
12.14. F. Hoffmann-La Roche AG
12.14.1. Business Overview
12.14.2. Key Executives
12.14.3. Product & Services
12.15. GE Healthcare
12.15.1. Business Overview
12.15.2. Key Executives
12.15.3. Product & Services
12.16. IRISYS, LLC
12.16.1. Business Overview
12.16.2. Key Executives
12.16.3. Product & Services
12.17. Johnson & Johnson
12.17.1. Business Overview
12.17.2. Key Executives
12.17.3. Product & Services
12.18. Mayne Pharma International Pty Ltd
12.18.1. Business Overview
12.18.2. Key Executives
12.18.3. Product & Services
12.19. Novartis AG
12.19.1. Business Overview
12.19.2. Key Executives
12.19.3. Product & Services
12.20. Ra Pharmaceuticals
12.20.1. Business Overview
12.20.2. Key Executives
12.20.3. Product & Services
12.21. Regeneron Pharmaceuticals, Inc
12.21.1. Business Overview
12.21.2. Key Executives
12.21.3. Product & Services
12.22. Samsung Bioepis
12.22.1. Business Overview
12.22.2. Key Executives
12.22.3. Product & Services
12.23. Thermo Fisher Scientific Inc.
12.23.1. Business Overview
12.23.2. Key Executives
12.23.3. Product & Services
12.24. Unither Pharmaceuticals
12.24.1. Business Overview
12.24.2. Key Executives
12.24.3. Product & Services
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing